Clorox (NYSE:CLX - Get Free Report) had its target price hoisted by research analysts at JPMorgan Chase & Co. from $83.00 to $86.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has an "underweight" rating on the stock. JPMorgan Chase & Co.'s target price would indicate a potential downside of 6.77% from the stock's previous close.
Other equities analysts have also recently issued research reports about the company. Weiss Ratings reiterated a "hold (c-)" rating on shares of Clorox in a report on Tuesday, October 6th. Wells Fargo & Company boosted their price objective on Clorox from $85.00 to $90.00 and gave the stock an "equal weight" rating in a report on Tuesday. Evercore upgraded shares of Clorox from an "underperform" rating to a "hold" rating and set a $99.00 target price on the stock in a research report on Monday. Zacks Research cut shares of Clorox from a "hold" rating to a "strong sell" rating in a research report on Thursday, October 29th. Finally, UBS Group set a $88.00 price target on shares of Clorox in a research note on Tuesday. One analyst has rated the stock with a Buy rating, twelve have issued a Hold rating and four have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Reduce" and a consensus target price of $93.29.
Get Our Latest Stock Report on Clorox
Clorox Price Performance
CLX stock traded up $2.34 during midday trading on Tuesday, reaching $92.24. 1,661,875 shares of the company's stock traded hands, compared to its average volume of 2,645,659. The company has a 50-day simple moving average of $88.27 and a two-hundred day simple moving average of $99.92. Clorox has a 1-year low of $79.12 and a 1-year high of $128.90. The company has a market cap of $11.16 billion, a price-to-earnings ratio of 19.14, a PEG ratio of 2.91 and a beta of 0.59. The company has a quick ratio of 0.38, a current ratio of 0.66 and a debt-to-equity ratio of 15.80.
Clorox (NYSE:CLX - Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The company reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.48. The firm had revenue of $1.91 billion during the quarter, compared to analysts' expectations of $1.88 billion. Clorox had a net margin of 8.74% and a return on equity of 522.23%. The company's quarterly revenue was up 33.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.85 EPS. On average, analysts anticipate that Clorox will post 5.66 earnings per share for the current year.
Hedge Funds Weigh In On Clorox
A number of hedge funds and other institutional investors have recently made changes to their positions in CLX. Eliot Finkel Investment Counsel LLC grew its holdings in Clorox by 2.0% in the 3rd quarter. Eliot Finkel Investment Counsel LLC now owns 27,565 shares of the company's stock valued at $2,233,000 after buying an additional 530 shares in the last quarter. Alps Advisors Inc. acquired a new position in shares of Clorox in the 3rd quarter valued at approximately $5,316,000. Ashton Thomas Private Wealth LLC lifted its stake in Clorox by 9.0% during the third quarter. Ashton Thomas Private Wealth LLC now owns 7,844 shares of the company's stock worth $635,000 after purchasing an additional 649 shares during the last quarter. Canvas Wealth Advisors LLC boosted its stake in Clorox by 18.6% in the third quarter. Canvas Wealth Advisors LLC now owns 111,481 shares of the company's stock valued at $9,885,000 after buying an additional 17,455 shares in the last quarter. Finally, Kestra Advisory Services LLC grew its holdings in shares of Clorox by 11.3% during the 3rd quarter. Kestra Advisory Services LLC now owns 29,943 shares of the company's stock valued at $2,426,000 after purchasing an additional 3,047 shares during the last quarter. 78.53% of the stock is owned by institutional investors.
Trending Headlines about Clorox
Here are the key news stories impacting Clorox this week:
- Positive Sentiment: Quarterly results exceeded expectations. Clorox reported adjusted earnings of $1.55 per share, well above the $1.07 consensus estimate, while revenue rose 33.3% year over year to $1.91 billion, topping the $1.88 billion forecast. Clorox Surpasses Q1 Earnings and Revenue Estimates
- Positive Sentiment: Margin recovery efforts are showing progress. Productivity gains, strategic pricing and anticipated savings from the GOJO integration are helping offset higher input costs, supporting management’s confidence in its recovery plans. Productivity Gains and Strategic Pricing Drive Margin Recovery
- Positive Sentiment: Analyst sentiment improved. Evercore ISI upgraded Clorox from “underperform” to “in line” with a $99 price target, citing the new CEO’s turnaround experience and potential for earnings recovery. Evercore ISI Upgrades Clorox
- Neutral Sentiment: Fiscal 2027 guidance was maintained. Clorox forecasts adjusted EPS of $5.70-$6.00 and revenue of $7.6 billion-$7.7 billion, broadly in line with analyst expectations. Clorox Reports Fiscal 2027 Results
- Negative Sentiment: Cost inflation remains a key risk. Management expects rising input costs and margin pressures to push results toward the lower end of its EPS range, increasing the importance of pricing actions, productivity savings and the GOJO integration. Clorox Earnings Call Highlights Inflation and Margin Pressures
About Clorox
(
Get Free Report)
The Clorox Company, founded in 1913 and headquartered in Oakland, California, is a consumer and professional products company. It began with household bleach and has expanded into a portfolio of brands serving cleaning, household, personal care, food, and professional markets.
Its brands include Clorox disinfecting and cleaning products, Pine-Sol cleaners, Liquid-Plumr drain care, Kingsford charcoal, Fresh Step and Scoop Away cat litter, Hidden Valley dressings and dips, Brita water filtration products, and Burt's Bees personal care items.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Clorox, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clorox wasn't on the list.
While Clorox currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.